Here are the 10-Q quarterly reports from Bowen Acquisition Corp Rights (BOWNR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BOWNR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOWNR filings page.
Bowen Acquisition Corp (BOWN) reported net income of $1,069,485 for the six months ended June 30, 2026, versus a net loss of $1,289,691 a year earlier. The result included a $1,096,351 gain on settlement of its forward purchase agreement and $127,281 of trust-account interest; operating costs were $118,653. The company had no operating revenue.
At June 30, cash was $4,093, the working-capital deficit was $1,428,255, and the trust account held $2,190,570. Management said substantial doubt about the company’s ability to continue as a going concern remained, despite pursuing its Qianzhi business combination and an approved extension of the deadline to December 31, 2026. The business combination remained pending required regulatory approvals. Disclosure controls were ineffective due to a material weakness tied to the lack of a qualified SEC reporting professional.
Nasdaq delisting of the units, ordinary shares, and rights became effective July 20, 2026. After June redemptions, 188,742 public shares remained as of June 30.
Bowen Acquisition Corp reported a $20,822 net loss for the three months ended March 31, 2026, compared with a $2,039,997 net loss a year earlier. At quarter-end it had $6,996 in cash and cash equivalents, $7,741,246 in its trust account, and a $2,458,756 working capital deficit. Management said these conditions raise substantial doubt about its ability to continue as a going concern and concluded its plans do not alleviate that doubt. It intends to pursue the Qianzhi business combination and fund shortfalls through extension loans and other financing arrangements.
The proposed combination with Shenzhen Qianzhi BioTechnology Co. Ltd. remained pending required regulatory approvals, and shareholders approved extending the combination deadline to as late as December 31, 2026. Bowen also reported ineffective disclosure controls as of March 31, 2026, due to a material weakness related to the lack of a qualified SEC reporting professional. The delisting from Nasdaq became effective at the opening of trading on July 20, 2026.